CRISPR‐Cas Assays for Protein Detection: Strategies and Clinical Applications
Small Methods · 05.11.2026
DOI: 10.1002/smtd.71186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, online erschienen am 05.11.2026. Verfasst von Shaokun Dong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center …. Die Arbeit nennt 182 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, CAS Project for Young Scientists in Basic Research.
Abstract (Originalsprache)
Measurement of protein biomarkers with high accuracy is critical for disease diagnostics and prognostic monitoring. However, conventional analytical platforms for protein detection suffer from insufficient sensitivity for low‐abundance targets and require time‐consuming, multi‐step workflows. The CRISPR‐Cas system is emerging as a powerful tool for protein analysis, with advantages including high programmability, excellent sensitivity, and compatibility with diverse readouts. This review presents a systematic overview of recent advances in CRISPR‐based protein assays. We first summarize the design principles of aptamer‐, antibody‐, and enzyme‐mediated systems that convert protein recognition events into CRISPR‐activatable nucleic acid signals. We next examine the signal amplification and readout strategies, such as direct CRISPR activation, enzyme‐mediated nucleic acid amplification, and enzyme‐free DNA nanotechnology, along with colorimetric, fluorescent, or electrochemical signal outputs. We also review applications of these assays in infectious diseases, cancer, and Alzheimer's disease. Finally, we discuss challenges and perspectives for next‐generation CRISPR‐based protein detection platforms in clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing, China.
- School of Future Technology, University of Chinese Academy of Sciences, Beijing, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
ORCID-Profile: Shuai Zhao, Liqin Zhang, Jiashu Sun
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- CAS Project for Young Scientists in Basic Research
- the Strategic Priority Research Program of the Chinese Academy of Sciences
- China Postdoctoral Science Foundation
- Young Elite Scientists Sponsorship Program of the Beijing High Innovation Plan
- National Key Research and Development Program of China
Zitieren
APA
Dong, S., Zhao, S., Deng, J., Zhang, L., & Sun, J. (2026). CRISPR‐Cas Assays for Protein Detection: Strategies and Clinical Applications. Small Methods. https://doi.org/10.1002/smtd.71186
Vancouver
Dong S, Zhao S, Deng J, Zhang L, Sun J. CRISPR‐Cas Assays for Protein Detection: Strategies and Clinical Applications. Small Methods. 2026. doi:10.1002/smtd.71186
BibTeX
@article{Dong2026,
author = {Dong, Shaokun and Zhao, Shuai and Deng, Jinqi and Zhang, Liqin and Sun, Jiashu},
title = {CRISPR‐Cas Assays for Protein Detection: Strategies and Clinical Applications},
journal = {Small Methods},
year = {2026},
doi = {10.1002/smtd.71186}
}
EUVIMED